Credit: Carl/Adobe Stock

The mifepristone case, FDA v. Alliance for Hippocratic Medicine, attracted a lot of national attention not only because of its implications for reproductive rights, but also because of the question related to the FDA's regulatory power. On June 13, 2024, the decision of the Supreme Court of the United States resulted in access to mifepristone, an abortion medication, remaining unchanged, but the decision was based on a procedural issue rather than an effort to protect reproductive rights.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Benefits Sales Strategies
Broker Regulation
Core and Group Health
Health Care Reform
C-Suite
Employer-Paid